Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 95Myelodysplastic Syndromes 26Recurrence 25Lymphoma, Non-Hodgkin 24Neoplasms 21Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Large B-Cell, Diffuse 15Leukemia 12Lymphoma, Follicular 10Multiple Myeloma 9Hematologic Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell 6Lymphoma 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 4Myeloproliferative Disorders 4Leukemia, Biphenotypic, Acute 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3GATA2 Deficiency 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Primary Myelofibrosis 2Immunoglobulin Light-chain Amyloidosis 2Colorectal Neoplasms 2

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Bevacizumab 2venetoclax 1toripalimab 1tanespimycin 1ivosidenib 1itacitinib 1durvalumab 1capivasertib 1birinapant 1baricitinib 1Zoledronic Acid 1Thalidomide 1Taxes 1Radiotherapy 1Paclitaxel 1Medicare Part B 1Leucovorin 1Irinotecan 1Immunoglobulin G 1INCB039110 1IFL protocol 1Filgrastim 1Disulfides 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Chondrosarcoma × venetoclax × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡